AstraZeneca’s immunotherapy combination including its checkpoint inhibitor drug Imfinzi has failed to improve overall survival in a first-line lung cancer trial – an indication where Merck
GlaxoSmithKline plans to carry out clinical trials on its pancreatic drug hopeful, GSK547, following promising results when treating mice and laboratory-grown tumour cells.
The FDA has granted a fast review for Roche/Genentech’s Tecentriq in combination with Celgene’s Abraxane for certain patients with tough-to-treat ‘triple negative’ breast cancer.
The US Food and Drug Administration (FDA) has granted AstraZeneca priority review for its ovarian cancer drug Lynparza – and the company has also revealed positive results for its diabetes
AstraZeneca has said it will continue pricing negotiations with the NHS and NICE after the cost-effectiveness body said the tablet formulation of Lynparza (olaparib) is too expensive for re
Bristol-Myers Squibb and AbbVie have picked up another FDA approval for their multiple myeloma drug Empliciti that they hope will help drive uptake of the drug.